Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503783
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 PositiveNegative Breast Cancer and Other Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase I Study to Evaluate the Safety Tolerability Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 PositiveNegative Breast Cancer and Other Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an open multicenter dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety tolerability pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in patients with locally advanced or metastatic HER2 positivenegative breast cancer and other solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None